Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis
Metrics: PDF 2153 views | HTML 1721 views | ?
Cuiling Zhou1,*, Donglan Liu2,*, Jie Li3,*, Huanhuan Sun1, Xiaobin Zheng4, Shuncong Wang1, Guobin Hong5, Saradhi Mallampati6, Hongliu Sun7, Xiuling Zhou1, Zhibin Cheng1, Hongyu Zhang1, Haiqing Ma1
1Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China
2Department of Gastroenterology, Cancer Hospital of Jiangxi Province, Nanchang, Jiangxi 330029, China
3Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China
4Department of Respiratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China
5Department of Radiology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China
6Department of Laboratory Medicine and the Center for Stem Cell and Developmental Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
7Department of Pathology, University of Michigan, Ann Arbor, MI 48201, USA
*These authors have contributed equally to this work
Haiqing Ma, email: [email protected]
Hongyu Zhang, email: [email protected]
Keywords: advanced non-small-cell lung cancer, overall survival, combination treatment of DC-CIKs, chemotherapy, meta-analysis
Received: July 10, 2016 Accepted: November 07, 2016 Published: November 16, 2016
This study was aimed to investigate the efficacy and safety of the combination treatment of dendritic cells co-cultured with cytokine-induced killer cells and chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC). Literatures were searched from the Cochrane Library Central, PubMed, Web of Science and EMBASE. The primary endpoint of interest was overall survival (OS), and secondary endpoints were disease control rate (DCR) and progression free survival (PFS). Finally 7 trials published between January 2005 and March 2016 met inclusion criteria and totally 610 patients were enrolled. The combination group showed advance in DCR (RR = 1.31, 95% CI = 1.13-1.52, p = 0.0004), 1-year OS (RR = 1.18, 95% CI = 1.05-1.33, p = 0.007), and 2-year OS (RR = 1.37, 95% CI = 1.10-1.70, p = 0.005), with statistical significance. The proportions of CD3+ T cells (p = 0.002), NK cells (p = 0.02) and NKT cells (p = 0.001) were significantly higher in the peripheral blood of combination group, compared with those of the control group. Moreover, adverse reactions were obviously decreased in the combination group. However, no significant difference was identified in ORR and PFS between two groups (p > 0.05). In conclusion, the combination therapy was safe and applicable for patients with advanced NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.